Service Hospitalo-Universitaire de Pharmaco-Toxicologie, Hospices Civils de Lyon, Bât. A-162, avenue Lacassagne, 69424 Cedex 03, Lyon, France.
Faculté de Santé, Université Paris-Est Créteil, EA 7379, Créteil, France.
Syst Rev. 2023 Jun 21;12(1):101. doi: 10.1186/s13643-023-02256-8.
Knowledge about the risks of drugs during pregnancy is continuously evolving due to the frequent publication of a large number of epidemiological studies. Systematic reviews and meta-analyses therefore need to be regularly updated to reflect these advances. To improve dissemination of this updated information, we developed an initiative of real-time full-scale living meta-analyses relying on an open online dissemination platform ( www.metapreg.org ).
All living meta-analyses performed in this project will be conducted in accordance with this master protocol after adaptation of the search strategy. A systematic literature search of PubMed and Embase will be performed. All analytical studies (e.g., cohort, case-control, randomized studies) reporting original empirical findings on the association between in utero exposure to drugs and adverse pregnancy outcomes will be included. Study screening and data extraction will be performed in a semi-automation way supervised by a biocurator. A risk of bias will be assessed using the ROBINS-I tools. All clinically relevant pregnancy adverse outcomes (malformations, stillbirths, neuro-developmental disorders, pre-eclampsia, etc.) available in the included studies will be pooled through random-effects meta-analysis. Heterogeneity will be evaluated by I statistics.
Our living systematic reviews and subsequent updates will inform the medical, regulatory, and health policy communities as the news results evolve to guide decisions on the proper use of drugs during the pregnancy.
Open Science Framework (OSF) registries.
由于大量流行病学研究的频繁发表,关于孕期药物风险的知识在不断发展。因此,系统评价和荟萃分析需要定期更新,以反映这些进展。为了更好地传播这些更新的信息,我们开发了一个实时全面的实时荟萃分析计划,该计划依赖于一个开放的在线传播平台(www.metapreg.org)。
本项目中进行的所有实时荟萃分析都将根据这个主方案进行,同时适应搜索策略。将对 PubMed 和 Embase 进行系统文献检索。所有分析性研究(例如队列研究、病例对照研究、随机研究),只要报告了子宫内暴露于药物与不良妊娠结局之间的关联的原始经验发现,都将被纳入。研究筛选和数据提取将以半自动方式进行,由生物策展人监督。使用 ROBINS-I 工具评估偏倚风险。所有在纳入研究中可用的临床相关妊娠不良结局(畸形、死胎、神经发育障碍、子痫前期等)将通过随机效应荟萃分析进行汇总。通过 I 统计评估异质性。
随着新结果的发展,我们的实时系统评价和随后的更新将为医疗、监管和卫生政策界提供信息,以指导在怀孕期间适当使用药物的决策。
开放科学框架(OSF)登记处。